pudexacianinium chloride

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Intraoperative Ureter Visualization

Conditions

Intraoperative Ureter Visualization, Abdominolpelvic Surgery

Trial Timeline

Aug 2, 2023 → Jan 16, 2025

NCT ID

NCT05754333

About pudexacianinium chloride

pudexacianinium chloride is a phase 3 stage product being developed by Astellas Pharma for Intraoperative Ureter Visualization. The current trial status is completed. This product is registered under clinical trial identifier NCT05754333. Target conditions include Intraoperative Ureter Visualization, Abdominolpelvic Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05999747	Phase 3	Completed	Mar 19, 2024	Oct 13, 2025	Intraoperative Ureter Visualization
NCT05754333	Phase 3	Completed	Aug 2, 2023	Jan 16, 2025	Intraoperative Ureter Visualization
NCT05495581	Phase 1	Completed	Aug 25, 2022	May 8, 2023	Healthy Volunteers
NCT05457842	Phase 2	Terminated	Aug 10, 2022	Sep 20, 2022	Sentinel Lymph Node Biopsy
NCT04238481	Phase 2	Completed	Oct 6, 2020	Nov 29, 2021	Laparoscopic/Minimally Invasive Colorectal Surgery

Competing Products

3 competing products in Intraoperative Ureter Visualization

See all competitors

Product	Company	Stage	Hype Score
pudexacianinium chloride	Astellas Pharma	Phase 3	77
Rocuronium	Merck	Pre-clinical	23
Floseal	Baxter	Approved	82

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved